Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 316 to 330 of 371 results for hypertension

  1. Type 2 diabetes in adults (QS209)

    This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.

  2. CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)

    NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .

  3. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

    Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.

  4. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)

    This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.

  5. Patiromer for treating hyperkalaemia (TA623)

    Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.

  6. Remote ECG interpretation consultancy services for cardiovascular disease (MIB152)

    NICE has developed a medtech innovation briefing (MIB) on remote ECG interpretation consultancy services for cardiovascular disease .

  7. Acute heart failure (QS103)

    This quality standard covers the care of adults (aged 18 and over) with suspected or confirmed acute heart failure. It describes high-quality care in priority areas for improvement.

  8. Psoriasis (QS40)

    This quality standard covers assessing and managing psoriasis in adults, young people and children. It describes high-quality care in priority areas for improvement.

  9. Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (TA667)

    Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg.

  10. What is the efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific antiviral drugs or COVID-specific neutralising monoclonal antibodies in people who do not need supplemental oxygen and are within 7 days of symptom onset?

    (but not limited to): • aged 60 or over• immunosuppression• obesity• hypertension• chronic lung disease• cardiovascular disease•...

  11. What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?

    (but not limited to): • aged 60 or over• immunosuppression• obesity• hypertension• chronic lung disease• cardiovascular disease•...

  12. Treatment for people with an IOP of 22 or 23 mmHg:- What is the clinical and cost effectiveness of treating an intraocular pressure (IOP) of 22 or 23 mmHg in people with normal optic discs and visual fields?

    between 25% and 35% from baseline. However, more recently the Ocular Hypertension Treatment Study (OHTS) enrolled people with an IOP...

  13. Ruxolitinib for treating polycythaemia vera (TA921)

    Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.

  14. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (HTG735)

    Evidence-based recommendations on home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome.

  15. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.